Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.
about
The PCSK9 decadeFrom proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsEfficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaAncestry and other genetic associations with plasma PCSK9 response to simvastatin.Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trialsMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A cholesterol-lowering VLP vaccine that targets PCSK9Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin.Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapyImpacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsNutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.Do statins lower testosterone and does it matter?Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Anti-PCSK9 therapies for the treatment of hypercholesterolemia.Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?Novel strategies for managing dyslipidemia: treatment beyond statins.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Seventeen years of statin pharmacogenetics: a systematic review.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.Pleiotropic Effects of Statins on the Cardiovascular System.The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.PCSK9 inhibitors: A new era of lipid lowering therapy.Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Isolation and characterization of the circulating truncated form of PCSK9The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
P2860
Q24615397-9A22F90F-D646-404B-9289-21DAFB7486CCQ26741078-50138863-5648-4175-AE0B-17381F3D4D73Q33728343-9D092528-0053-4267-B6CF-BF5ED1F0C316Q34157965-A11A2C4A-8761-4468-92C2-9D93D7988E66Q34297213-21EEF74C-24D1-482B-9F19-65179C527C9AQ34458693-1F2006C0-37B1-47E0-8CF8-939623134725Q34496015-29B64EA9-F8E6-48E6-99FC-7E05AAB90D80Q34588435-7A9B46D0-F795-4877-B593-47117802081EQ35141471-617A8CBE-B2F9-460C-9481-27150E20EAB8Q35194029-98345EAD-3FBA-4364-B519-83A4D3976EADQ35671077-DBE153C2-59A7-4A5F-9A4D-4F6F4FFFB200Q36335047-3DADA4C8-4ADC-43BE-A522-3340BA3D15D4Q36753549-FC382ED4-A12E-4CAA-9E57-038B08EC201CQ37596775-08C8F836-D317-4D39-AB81-9BE7E54D72CBQ38001736-E6A57CE0-2DE4-43CC-BB82-48C1E4C16E32Q38039980-ED506185-E5C0-4434-B9F2-6162C91BA6F8Q38067460-03B1B1F5-EA48-495B-A375-947A9DE4F237Q38067634-6AA3958B-637D-4B2F-A36F-C239C1C75717Q38074335-F823DAD3-8AEC-4027-81F6-E655DCD8DA89Q38095872-E455CDAA-396B-455B-B297-1232392FCDACQ38109960-F5C75425-0B66-4AFA-8584-916B669B592BQ38172643-9ABE079F-6C76-45E7-8B0A-C6269A07EA1CQ38548750-78190E47-9B4C-4394-8C9C-DFEE6626F0CEQ38613935-713EEA73-6BE7-4656-BFA4-83661D50C83EQ38643197-0A5D314F-9397-41E4-AFC8-AD8793E0429DQ38670109-DC63A2FF-F916-49DA-8B25-3945A7727737Q38846832-68E03498-8583-4B29-9C21-6A5B9CC63C42Q38999690-9F004CFB-A09F-4C26-B528-0DABC224DFC9Q39069187-E2B9DCD9-7D41-4A17-B70B-B9240ED66E50Q39080645-7A8CF5E0-D6E7-4D97-930D-1DE6A20176CFQ39176815-AE8E3450-A5F5-4FA2-AE0C-157102DEE986Q39353845-39DDF63A-D5EA-44B8-BDAB-FF23703E1557Q41064722-79E95091-0234-4D7F-A595-FD1971E8307DQ41328708-F21E3DAA-D724-4FB4-B0CE-C6A645A2FC64Q41503652-59D71584-CE92-407A-A7AC-BBA5FD0566E0Q41518234-E98C568D-F9F4-4A0C-B10C-03F3C7F5CBA2Q42367561-7D176AC2-2FB0-4AD7-813F-12E22E1D81D1Q44496513-CC000091-64B4-47F4-AC7F-A345BD6C520AQ44811412-2039BA42-DAB8-4D84-9D50-A8768E86E8DDQ47377607-B131A360-853F-4F0D-B8CC-28668435D10F
P2860
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rosuvastatin, proprotein conve ...... l response: the JUPITER trial.
@en
type
label
Rosuvastatin, proprotein conve ...... l response: the JUPITER trial.
@en
prefLabel
Rosuvastatin, proprotein conve ...... l response: the JUPITER trial.
@en
P2093
P1433
P1476
Rosuvastatin, proprotein conve ...... l response: the JUPITER trial.
@en
P2093
Daniel I Chasman
Jean G MacFadyen
Paul M Ridker
Suzanne Benjannet
Zuhier Awan
P304
P356
10.1373/CLINCHEM.2011.172932
P407
P577
2011-11-07T00:00:00Z